Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib Adjuvant Therapy in High-risk Stage I EGFRm NSCLC
NCT05686434Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Oct 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib, sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Oct 2022; status: recruiting.
02
Drugs
Beyond the preview
Go deeper on NCT05686434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05686434.